AstraZeneca reviews

Cuts, cuts, cuts as the company goes through a patent drought. Research head has made clear that he does not believe in informatics, so the group has been heavily cut. Success of the company does not necessarily mean success for the employee or for their site. Layoffs and site closures are now frequent, and I don't think there is any company that is better at doing reorgs like clockwork every two years or less. Benefits and perks are cut every year. The company is focused on large molecules so the small-molecule sites, like Waltham, are even more at risk of closure. It's hard to advance here, particularly without relocating. There are deep cultural rifts between the US, UK and Sweden and they are not acknowledged or properly addressed; the result is a charged political environment where people don't understand each others' styles or meanings. A lot of people are leaving.

Slightly out of date processes. Averse to change and risk. Reluctance to investigate new ideas.